Memorial Sloan Kettering researchers identified a molecular switch, ZFP36L2, that governs gut-cell survival programs—and colorectal cancer appears to hijack the same mechanism to enable spread. The work frames tumor progression around reprogrammed stress-response biology in damaged intestinal cells. In parallel, researchers reported a peptide strategy in Nature that induces immunogenic, membrane-disrupting cancer cell death. Using a pH-responsive construct, the approach aims to make tumor cells “visible” to immunity by forcing a controlled rupturing event linked to immunogenic cell death.